Also published in ncbi.nlm.nih.gov:
Immunological Resolution of Human Chronic Graft-versus-Host Disease.
x hide permanently

MELK is a novel therapeutic target in high-risk neuroblastoma.

ncbi.nlm.nih.gov

MELK is a novel therapeutic target in high-risk neuroblastoma.

Oncotarget. 2018 Jan 05;9(2):2591-2602

Authors: Guan S, Lu J, Zhao Y, Yu Y, Li H, Chen Z, Shi Z, Liang H, Wang M, Guo K, Chen X, Sun W, Bieerkehazhi S, Xu X, Sun S, Agarwal S, Yang J

Abstract Maternal embryonic leucine zipper kinase (MELK) is known to modulate intracellular signaling and control cellular processes. However, the role of MELK in oncogenesis is not well defined.

Mentions: MYCN